Trial Profile
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Bacteraemia; Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia; Osteomyelitis; Skin and soft tissue infections
- Focus Adverse reactions; Pharmacokinetics
- 08 Jan 2018 Results published in the Antimicrobial Agents and Chemotherapy
- 25 Apr 2017 Results assessing pharmacokinetics of fixed dose telavancin presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
- 25 Apr 2017 According to a Theravance Biopharma media release,data from this trial was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).